Form 8-K Revolution Medicines, For: Aug 26
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom forecasts quarterly sales below estimates amid rising custom AI chip competition
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Revolution Medicines prices RASONQUE at $39,800 per month
August 26, 2026 1:54 PM EDT(Updated - August 26, 2026 2:04 PM EDT)
The U.S. Food and Drug Administration approved Revolution Medicines' (NASDAQ: RVMD) RASONQUE (daraxonrasib) on August 26, 2026, for adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for... More
